Number of patients fulfilling the various criteria sets and performance of the various criteria sets
| PsA versus control | ASAS peripheral | ESSG | Amor | CASPAR |
|---|---|---|---|---|
| PsA N pos. (sensitivity) | 78 (52.0)* | 39 (26.0)* | 55 (36.7)* | 133 (88.7)* |
| LR+ | 5.11 | 2.26 | – | 20.04 |
| LR− | 0.53 | 0.84 | 0.63 | 0.12 |
| SpA vs control | ASAS peripheral | ESSG | Amor | CASPAR |
|---|---|---|---|---|
| SpA N pos. (sensitivity) | 37 (48.7)* | 37 (48.7)* | 20 (26.3)* | 4 (5.3) |
| LR+ | 4.78 | 4.2 | − | 1.19 |
| LR− | 0.57 | 0.58 | 0.74 | 0.99 |
| Control N neg. (specificity) | 203 (89.8) | 200 (88.5) | 226 (100) | 216 (95.6) |
↵* marks a p value <0.05, PsA-group or SpA-group is significantly different than the control group on fulfilling the criteria.
ASAS, Assessment of SpondyloArthritis international Society; CASPAR, classification of psoriatic arthritis; ESSG, European Spondylarthropathy Study Group; LR+, positive likelihood ratio; LR−, negative likelihood ratio.